Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial

What Was Tested

The paper reports a study of Glucagon and Oxyntomodulin, published as a randomized controlled trial.

The measurement of proglucagon-derived peptides (PGDPs) is a challenging task mainly due to major overlaps in their molecular sequence in addition to their low circulating levels.

Here, the researchers present the technical characteristics of novel ELISA assays measuring C-peptide and all six PGDPs including, for the first time, major proglucagon fragment (MPGF), and the researchers validate them by performing a pilot in vivo cross-over randomized clinical trial on whether coffee consumption may affect levels of circulating PGDPs.

Who Took Part

The study group was 33 subjects.

How the Study Was Run

The researchers set it up as a randomized, crossover and pilot study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the subjects took both Glucagon and the comparison in turn, acting as their own control.

It is described as a pilot, a small early test of whether a larger Glucagon study would be practical.

What Was Measured

The measurement of proglucagon-derived peptides (PGDPs) is a challenging task mainly due to major overlaps in their molecular sequence in addition to their low circulating levels.

Here, the researchers present the technical characteristics of novel ELISA assays measuring C-peptide and all six PGDPs including, for the first time, major proglucagon fragment (MPGF), and the researchers validate them by performing a pilot in vivo cross-over randomized clinical trial on whether coffee consumption may affect levels of circulating PGDPs.

Topics PubMed links to this paper include C-Peptide, Caffeine, Coffee, Glicentin, Glucagon, Glucagon-Like Peptide 1 and Oxyntomodulin.

Author keywords: Diabetes, GLP-1, GLP-2 and Obesity.

What This Means in Plain Language

The paper is a randomized, crossover and pilot study of Glucagon and Oxyntomodulin in 33 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Glucagon compound page and the Oxyntomodulin compound page, all human trials.